NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
Clinical Trials
4 trialsNCT02658396 2017-07-05
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT01680796 2013-02-20
Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
University of Florida
Phase 1 Withdrawn